Anemia has an unfavorable impact on quality of life in chronic lymphocytic leukemia (CLL), increases the likelihood of receiving blood transfusions, and eventually has a negative impact on overall survival. Although discrepancies in perception of health-related quality of life between doctors and patients lead to the undertreatment of anemia, CLL patients undergoing chemotherapy who have a hemoglobin level <10 g/dL should be considered for treatment with erythropoiesis-stimulating agents. For hemoglobin values of 10-12 g/dL, the role of performance status and comorbidities should not be underestimated. In this setting, the evaluation of physical fitness using the Cumulative Illness Rating Scale should help physicians to identify those patients with hemoglobin levels of 10-12 g/dL who are suitable for therapy with erythropoiesis-stimulating agents. Finally, the increasing use of aggressive approaches to therapy should encourage physicians towards appropriate management of chemotherapy-induced anemia in CLL patients.

Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia / Molica, S.; Mirabelli, R.; Molica, M.; Levato, L.; Mauro, Francesca Romana; Foa, Roberto. - In: CANCER MANAGEMENT AND RESEARCH. - ISSN 1179-1322. - 3:(2011), pp. 211-217. [10.2147/CMR.S17470]

Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.

MAURO, Francesca Romana;FOA, Roberto
2011

Abstract

Anemia has an unfavorable impact on quality of life in chronic lymphocytic leukemia (CLL), increases the likelihood of receiving blood transfusions, and eventually has a negative impact on overall survival. Although discrepancies in perception of health-related quality of life between doctors and patients lead to the undertreatment of anemia, CLL patients undergoing chemotherapy who have a hemoglobin level <10 g/dL should be considered for treatment with erythropoiesis-stimulating agents. For hemoglobin values of 10-12 g/dL, the role of performance status and comorbidities should not be underestimated. In this setting, the evaluation of physical fitness using the Cumulative Illness Rating Scale should help physicians to identify those patients with hemoglobin levels of 10-12 g/dL who are suitable for therapy with erythropoiesis-stimulating agents. Finally, the increasing use of aggressive approaches to therapy should encourage physicians towards appropriate management of chemotherapy-induced anemia in CLL patients.
2011
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia / Molica, S.; Mirabelli, R.; Molica, M.; Levato, L.; Mauro, Francesca Romana; Foa, Roberto. - In: CANCER MANAGEMENT AND RESEARCH. - ISSN 1179-1322. - 3:(2011), pp. 211-217. [10.2147/CMR.S17470]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/417750
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? ND
social impact